AI assistant
DEXCOM INC — Director's Dealing 2022
Sep 6, 2022
30198_dirs_2022-09-06_635e1e23-9638-4571-8e03-057f48293887.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2022-09-01
Reporting Person: Dolan Matthew Vincent (SVP Corporate Strategy-Develop)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-09-01 | Common Stock | S | 5 | $81.63 | Disposed | 26536 | Direct |
Footnotes
F1: On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2: Adjusted to reflect Dexcom's 4-for-1 stock split, effective on June 10, 2022. Included in this number are 26,536 unvested restricted stock units, 11,556 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,192 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 6,788 of which were granted on March 8, 2020 and shall vest through March 8, 2023.